Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study.

Boyle DL, DePrimo SE, Calderon C, Chen D, Dunford PJ, Barchuk W, Firestein GS, Thurmond RL.

Inflamm Res. 2019 Apr;68(4):261-274. doi: 10.1007/s00011-019-01218-y. Epub 2019 Feb 9.

PMID:
30739130
2.

Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial.

Loesche MA, Farahi K, Capone K, Fakharzadeh S, Blauvelt A, Duffin KC, DePrimo SE, Muñoz-Elías EJ, Brodmerkel C, Dasgupta B, Chevrier M, Smith K, Horwinski J, Tyldsley A, Grice EA.

J Invest Dermatol. 2018 Sep;138(9):1973-1981. doi: 10.1016/j.jid.2018.03.1501. Epub 2018 Mar 17.

3.

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.

Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, Lin E, Wang X, Harmon CS, Heymach JV.

Br J Cancer. 2015 Mar 31;112(7):1199-205. doi: 10.1038/bjc.2015.73.

4.

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.

Harmon CS, DePrimo SE, Figlin RA, Hudes GR, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Williams JA, Eisen T, Motzer RJ.

Cancer Chemother Pharmacol. 2014 Jan;73(1):151-61. doi: 10.1007/s00280-013-2333-4. Epub 2013 Nov 13.

5.

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib.

Keyvanjah K, DePrimo SE, Harmon CS, Huang X, Kern KA, Carley W.

J Transl Med. 2012 Aug 16;10:165. doi: 10.1186/1479-5876-10-165.

6.

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.

Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, Lim HY, Kim JS, Lechuga MJ, Lanzalone S, Lin X, Faivre S.

J Transl Med. 2011 Jul 25;9:120. doi: 10.1186/1479-5876-9-120.

7.

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.

LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner KD, Tan W, Ricart AD.

Clin Cancer Res. 2010 Mar 15;16(6):1924-37. doi: 10.1158/1078-0432.CCR-09-1883. Epub 2010 Mar 9.

8.

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.

Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, Shah MH, Verweij J, Baum CM, Demetri GD.

Clin Cancer Res. 2009 Sep 15;15(18):5869-77. doi: 10.1158/1078-0432.CCR-08-2480. Epub 2009 Sep 8.

9.

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD.

Eur J Cancer. 2009 Jul;45(11):1959-68. doi: 10.1016/j.ejca.2009.02.011. Epub 2009 Mar 11.

PMID:
19282169
10.

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ.

J Clin Oncol. 2008 Aug 1;26(22):3743-8. doi: 10.1200/JCO.2007.15.5416.

PMID:
18669461
11.

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD.

J Clin Oncol. 2008 Apr 10;26(11):1810-6. doi: 10.1200/JCO.2007.14.5375. Epub 2008 Mar 17.

PMID:
18347007
12.

Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib.

DePrimo SE, Bello C.

Ann Oncol. 2007 Sep;18 Suppl 10:x11-9. Review.

13.

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.

Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ.

J Clin Oncol. 2007 Oct 20;25(30):4793-9. Erratum in: J Clin Oncol. 2008 Jan 20;26(3):514.

PMID:
17947727
14.

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.

Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ.

J Transl Med. 2007 Jul 2;5:32.

15.

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV.

Clin Cancer Res. 2007 May 1;13(9):2643-50.

16.

Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription.

Bebermeier JH, Brooks JD, DePrimo SE, Werner R, Deppe U, Demeter J, Hiort O, Holterhus PM.

J Mol Med (Berl). 2006 Nov;84(11):919-31. Epub 2006 Aug 24.

PMID:
16932916
17.

Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.

Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E, Nowell P, Deprimo SE, Sadis S, Eck S, Schuster SJ, Diehl JA, Wasik MA.

Blood. 2006 Sep 1;108(5):1744-50. Epub 2006 May 11.

18.

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI.

J Clin Oncol. 2006 Jan 1;24(1):16-24. Epub 2005 Dec 5.

PMID:
16330672
19.

Reg IV: a promising marker of hormone refractory metastatic prostate cancer.

Gu Z, Rubin MA, Yang Y, Deprimo SE, Zhao H, Horvath S, Brooks JD, Loda M, Reiter RE.

Clin Cancer Res. 2005 Mar 15;11(6):2237-43.

20.

Resveratrol-induced gene expression profiles in human prostate cancer cells.

Jones SB, DePrimo SE, Whitfield ML, Brooks JD.

Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):596-604.

21.

Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification.

DePrimo SE, Wong LM, Khatry DB, Nicholas SL, Manning WC, Smolich BD, O'Farrell AM, Cherrington JM.

BMC Cancer. 2003 Feb 7;3:3. Epub 2003 Feb 7.

22.

Transcriptional programs activated by exposure of human prostate cancer cells to androgen.

DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, Fero M, Tibshirani R, Brown PO, Brooks JD.

Genome Biol. 2002 Jun 14;3(7):RESEARCH0032. Epub 2002 Jun 14.

23.

Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells.

Schwarze SR, DePrimo SE, Grabert LM, Fu VX, Brooks JD, Jarrard DF.

J Biol Chem. 2002 Apr 26;277(17):14877-83. Epub 2002 Feb 8.

24.

Prevention of prostate cancer.

DePrimo SE, Shinghal R, Vidanes G, Brooks JD.

Hematol Oncol Clin North Am. 2001 Jun;15(3):445-57. Review.

PMID:
11525290
25.

Regulation of p53 expression by the RAS-MAP kinase pathway.

Agarwal ML, Ramana CV, Hamilton M, Taylor WR, DePrimo SE, Bean LJ, Agarwal A, Agarwal MK, Wolfman A, Stark GR.

Oncogene. 2001 May 3;20(20):2527-36.

26.

Mechanisms of G2 arrest in response to overexpression of p53.

Taylor WR, DePrimo SE, Agarwal A, Agarwal ML, Schönthal AH, Katula KS, Stark GR.

Mol Biol Cell. 1999 Nov;10(11):3607-22.

27.

In situ detection of frameshift mutations in mouse cells.

Cao J, DePrimo SE, Hersh MN, Stringer JR.

Mutat Res. 1998 Nov 3;421(2):163-78.

PMID:
9852990
28.

Use of human placental alkaline phosphatase transgenes to detect somatic mutation in mice in situ.

DePrimo SE, Cao J, Hersh MN, Stringer JR.

Methods. 1998 Sep;16(1):49-61.

PMID:
9774516
29.

Cell cycle dependence of radiation-induced homologous recombination in cultured monkey cells.

Cao J, DePrimo SE, Stringer JR.

Mutat Res. 1997 Mar 21;374(2):233-43.

PMID:
9100846
30.

Human placental alkaline phosphatase as a histochemical marker of gene expression in transgenic mice.

DePrimo SE, Stambrook PJ, Stringer JR.

Transgenic Res. 1996 Nov;5(6):459-66.

PMID:
8840529

Supplemental Content

Loading ...
Support Center